522 related articles for article (PubMed ID: 33958572)
1. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
[TBL] [Abstract][Full Text] [Related]
2. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
[TBL] [Abstract][Full Text] [Related]
3. LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments.
Rizos CV; Skoumas I; Rallidis L; Skalidis E; Tziomalos K; Garoufi A; Anagnostis P; Sfikas G; Kotsis V; Doumas M; Kolovou G; Lambadiari V; Dima I; Kiouri E; Zacharis E; Agapakis D; Attilakos A; Antza C; Vlachopoulos C; Liberopoulos EN
Int J Cardiol; 2021 Dec; 345():119-124. PubMed ID: 34687802
[TBL] [Abstract][Full Text] [Related]
4. Patient Characteristics and Real-World Treatment Patterns Among Early Users of PCSK9 Inhibitors.
Rane PB; Patel J; Harrison DJ; Shepherd J; Leith A; Bailey H; Piercy J
Am J Cardiovasc Drugs; 2018 Apr; 18(2):103-108. PubMed ID: 28849360
[TBL] [Abstract][Full Text] [Related]
5. Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy.
Hartgers ML; Besseling J; Stroes ES; Wittekoek J; Rutten JHW; de Graaf J; Visseren FLJ; Imholz BPM; Roeters van Lennep JE; Huijgen R; Kastelein JJP; Hovingh GK
J Clin Lipidol; 2018; 12(4):972-980.e1. PubMed ID: 29934068
[TBL] [Abstract][Full Text] [Related]
6. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study).
Schettler VJ; Muellendorff F; Schettler E; Platzer C; Norkauer S; Julius U; Neumann CL
Ther Apher Dial; 2019 Oct; 23(5):467-473. PubMed ID: 30663261
[TBL] [Abstract][Full Text] [Related]
7. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways.
Cammisotto V; Baratta F; Castellani V; Bartimoccia S; Nocella C; D'Erasmo L; Cocomello N; Barale C; Scicali R; Di Pino A; Piro S; Del Ben M; Arca M; Russo I; Purrello F; Carnevale R; Violi F; Pastori D; Pignatelli P
Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281247
[No Abstract] [Full Text] [Related]
8. A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.
Davis LE; Pogge EK
High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):331-338. PubMed ID: 32651891
[TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
10. The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis.
Alshahrani A; Kholaif N; Al-Khnifsawi M; Zarif H; Mahzari M
Adv Ther; 2024 Feb; 41(2):837-846. PubMed ID: 38169062
[TBL] [Abstract][Full Text] [Related]
11. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 inhibitors in clinical practice: Novel directions and new experiences.
Rallidis LS; Skoumas I; Liberopoulos EN; Vlachopoulos C; Kiouri E; Koutagiar I; Anastasiou G; Kosmas N; Elisaf MS; Tousoulis D; Iliodromitis E
Hellenic J Cardiol; 2020; 61(4):241-245. PubMed ID: 31783124
[TBL] [Abstract][Full Text] [Related]
13. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9.
Edmiston JB; Brooks N; Tavori H; Minnier J; Duell B; Purnell JQ; Kaufman T; Wojcik C; Voros S; Fazio S; Shapiro MD
J Clin Lipidol; 2017; 11(3):667-673. PubMed ID: 28506388
[TBL] [Abstract][Full Text] [Related]
14. Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two-Lipid Center Real-World Experience.
Mandraffino G; Scicali R; Rodríguez-Carrio J; Savarino F; Mamone F; Scuruchi M; Cinquegrani M; Imbalzano E; Di Pino A; Piro S; Rabuazzo AM; Squadrito G; Purrello F; Saitta A
J Clin Lipidol; 2020; 14(2):231-240. PubMed ID: 32111581
[TBL] [Abstract][Full Text] [Related]
15. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.
Zafrir B; Jubran A
Cardiovasc Ther; 2018 Oct; 36(5):e12439. PubMed ID: 29863817
[TBL] [Abstract][Full Text] [Related]
16. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom.
Tai MH; Shepherd J; Bailey H; Williams N; Hatz M; Campos Tapias I; Catterick D; Worth G
Curr Med Res Opin; 2019 May; 35(5):829-835. PubMed ID: 30289004
[TBL] [Abstract][Full Text] [Related]
18. Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease.
Mallya UG; Boklage SH; Koren A; Delea TE; Mullins CD
Pharmacoeconomics; 2018 Jan; 36(1):115-126. PubMed ID: 29181773
[TBL] [Abstract][Full Text] [Related]
19. Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.
Schmidt N; Dressel A; Grammer TB; Gouni-Berthold I; Julius U; Kassner U; Klose G; König C; Koenig W; Otte B; Parhofer KG; Reinhard W; Schatz U; Schunkert H; Steinhagen-Thiessen E; Vogt A; Laufs U; März W
Atherosclerosis; 2018 Oct; 277():314-322. PubMed ID: 30270065
[TBL] [Abstract][Full Text] [Related]
20. Effect of Preoperative Administration of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor on Carotid Artery Stenting.
Shingai Y; Kimura N; Doijiri R; Takahashi K; Yokosawa M; Kanoke A; Kikuchi T; Sugawara T; Tominaga T
World Neurosurg; 2020 Mar; 135():e36-e42. PubMed ID: 31655235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
